- $102.28bn
- $124.59bn
- $195.27bn
- 79
- 70
- 91
- 94
Annual income statement for Cigna, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | R2021 December 31st | R2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 153,566 | 160,197 | 174,069 | 180,518 | 195,265 |
| Cost of Revenue | |||||
| Gross Profit | 25,079 | 24,003 | 22,951 | 23,500 | 25,177 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 145,491 | 148,040 | 166,269 | 170,406 | 188,228 |
| Operating Profit | 8,075 | 12,157 | 7,800 | 10,112 | 7,037 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | 6,570 | 10,868 | 6,790 | 8,397 | 5,513 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 5,120 | 8,489 | 5,420 | 6,782 | 5,372 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | 5,104 | 8,458 | 5,370 | 6,704 | 5,164 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 5,104 | 8,458 | 5,370 | 6,704 | 5,164 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 16 | 10.5 | 16.6 | 17.5 | 28.3 |
| Dividends per Share |